Literature DB >> 17925768

Diagnosis and management of pancreatic fistulae resulting in pancreatic ascites or pleural effusions in the era of helical CT and magnetic resonance imaging.

Dermot O'Toole1, Marie-Pierre Vullierme, Philippe Ponsot, Frédéric Maire, Valérie Calmels, Olivia Hentic, Pascal Hammel, Alain Sauvanet, Jacques Belghiti, Valérie Vilgrain, Philippe Ruszniewski, Philippe Lévy.   

Abstract

OBJECTIVES: Diagnosis of internal pancreatic fistulae (IPF) resulting in ascites or pleural effusions may be facilitated by multislice helical CT-scan and MR-pancreatography [MRP]). Conservative treatment with parenteral nutrition and somatostatin analogues (+/- pancreatic stenting) yields varying results. We aimed to evaluate the usefulness of helical CT and MRP in the diagnosis of IPF. The outcome of patients when the following stepwise treatment algorithm is applied is also descried: i) conservative (enteral nutrition and somatostatin analogues); ii) endoscopic stenting; iii) surgery.
METHODS: Sixteen consecutive patients (13 M; median age 42 (14-54) yrs) with chronic pancreatitis (alcoholic 15, hereditary 1) and an IPF were prospectively included between March-01 to December-03. All serous effusions (ascites, N=10; pleural effusion, N=6) contained high lipase [median: 7800 (506-59000) U/mL]. Patients with fistulae communicating with pancreatic pseudocysts were not included.
RESULTS: The diagnosis of IPF and its site were determined in 12/16 patients by CT and 14/15 patients by MRP (site of rupture: head: N=5; isthmus: N=5; body-tail: N=6) and confirmed by ERCP or surgery in 9. Localized atrophy of pancreatic parenchyma adjacent to pancreatic duct rupture was observed in 12 patients (75%). The median follow-up was 30 months (18-51). Early surgery was required in 3 patients (2 with infection of serous fluid at initial aspiration analysis). Thirteen entered the treatment algorithm: - seven patients responded favorably (54%) to conservative treatment (enteral nutrition and somatostatin analogues); - pancreatic stenting, possible in 4 of 6 patients, was successful in closing the IPF in 2; - surgery was required in the 4 remaining patients. Preoperative localization of the rupture site was possible in all patients using non-invasive imaging thus guiding elective intervention in all patients requiring surgery.
CONCLUSION: Helical CT scan and MRP are useful in localizing MPD rupture sites and fistulae and may obviate the need for pancreatic opacification. A systematic treatment algorithm can be safely used starting with medical strategies (enteral nutrition safely replacing the parenteral route) progressing to endoscopy and finally surgery. Overall about 44% of patients require surgery initially or at follow-up.

Entities:  

Mesh:

Year:  2007        PMID: 17925768     DOI: 10.1016/s0399-8320(07)91918-1

Source DB:  PubMed          Journal:  Gastroenterol Clin Biol        ISSN: 0399-8320


  4 in total

1.  Therapeutic challenges of pancreatic ascites and the role of endoscopic pancreatic stenting.

Authors:  Sudhakar Karlapudi; Tomoya Hinohara; James Clements; Gene Bakis
Journal:  BMJ Case Rep       Date:  2014-08-21

2.  Optimizing management of pancreaticopleural fistulas.

Authors:  Marek Wronski; Maciej Slodkowski; Wlodzimierz Cebulski; Daniel Moronczyk; Ireneusz W Krasnodebski
Journal:  World J Gastroenterol       Date:  2011-11-14       Impact factor: 5.742

3.  Extension of nonoperative management of blunt pancreatic trauma to include grade III injuries: a safety analysis.

Authors:  Giacomo Pata; Claudio Casella; Ernesto Di Betta; Luigi Grazioli; Bruno Salerni
Journal:  World J Surg       Date:  2009-08       Impact factor: 3.352

Review 4.  Evidence-based clinical practice guidelines for chronic pancreatitis 2021.

Authors:  Kyoko Shimizu; Tetsuhide Ito; Atsushi Irisawa; Takao Ohtsuka; Hirotaka Ohara; Atsushi Kanno; Mitsuhiro Kida; Junichi Sakagami; Naohiro Sata; Yoshifumi Takeyama; Junko Tahara; Morihisa Hirota; Nao Fujimori; Atsushi Masamune; Satoshi Mochida; Nobuyuki Enomoto; Tooru Shimosegawa; Kazuhiko Koike
Journal:  J Gastroenterol       Date:  2022-08-22       Impact factor: 6.772

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.